PH12016501747B1 - Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof - Google Patents
Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereofInfo
- Publication number
- PH12016501747B1 PH12016501747B1 PH1/2016/501747A PH12016501747A PH12016501747B1 PH 12016501747 B1 PH12016501747 B1 PH 12016501747B1 PH 12016501747 A PH12016501747 A PH 12016501747A PH 12016501747 B1 PH12016501747 B1 PH 12016501747B1
- Authority
- PH
- Philippines
- Prior art keywords
- levofloxacin
- eye drops
- dosage
- solvate
- salt
- Prior art date
Links
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title abstract 8
- 229960003376 levofloxacin Drugs 0.000 title abstract 8
- 208000001860 Eye Infections Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title 2
- 239000012453 solvate Substances 0.000 title 2
- 229940054534 ophthalmic solution Drugs 0.000 title 1
- 239000002997 ophthalmic solution Substances 0.000 title 1
- 239000003889 eye drop Substances 0.000 abstract 7
- 229940012356 eye drops Drugs 0.000 abstract 7
- 208000011323 eye infectious disease Diseases 0.000 abstract 3
- 244000052616 bacterial pathogen Species 0.000 abstract 2
- 238000007796 conventional method Methods 0.000 abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010040281 | 2010-02-25 | ||
| PCT/JP2010/072685 WO2011104981A1 (ja) | 2010-02-25 | 2010-12-16 | レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016501747A1 PH12016501747A1 (en) | 2019-02-11 |
| PH12016501747B1 true PH12016501747B1 (en) | 2022-06-22 |
Family
ID=44506417
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2016/501747A PH12016501747B1 (en) | 2010-02-25 | 2010-12-16 | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
| PH1/2012/501674A PH12012501674A1 (en) | 2010-02-25 | 2010-12-16 | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/501674A PH12012501674A1 (en) | 2010-02-25 | 2010-12-16 | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120316158A1 (https=) |
| EP (1) | EP2540299B1 (https=) |
| JP (3) | JP5600056B2 (https=) |
| KR (2) | KR20130043611A (https=) |
| CN (1) | CN102770141A (https=) |
| BR (1) | BR112012021247A2 (https=) |
| CA (1) | CA2791190C (https=) |
| EA (1) | EA201290827A1 (https=) |
| ES (1) | ES2568647T3 (https=) |
| MX (1) | MX349603B (https=) |
| MY (1) | MY183483A (https=) |
| NZ (1) | NZ602126A (https=) |
| PH (2) | PH12016501747B1 (https=) |
| SG (1) | SG183427A1 (https=) |
| TW (1) | TWI488627B (https=) |
| WO (1) | WO2011104981A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12016501747B1 (en) * | 2010-02-25 | 2022-06-22 | Daiichi Sankyo Co Ltd | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
| CN103550144B (zh) * | 2013-10-25 | 2015-10-14 | 深圳朗欧医药集团有限公司 | 盐酸左氧氟沙星组合物注射液及其制备方法 |
| JP6363833B2 (ja) * | 2013-11-22 | 2018-07-25 | ナノシータ株式会社 | 薄膜状高分子構造体 |
| CN104606198A (zh) * | 2015-01-09 | 2015-05-13 | 周元铎 | 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用 |
| IT201900005280A1 (it) * | 2019-04-05 | 2020-10-05 | Ntc S R L | Composizione otologica |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3038722B2 (ja) | 1989-06-23 | 2000-05-08 | 日本電気株式会社 | 接合型電界効果トランジスタ |
| JP3192290B2 (ja) | 1993-08-04 | 2001-07-23 | カネボウ株式会社 | ポリエステル製耐熱ボトル |
| WO2003028664A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and forms thereof |
| EP1458391B1 (en) * | 2001-11-30 | 2007-09-05 | LG Life Sciences Ltd. | A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic |
| US20050009836A1 (en) | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| WO2005000307A1 (en) * | 2003-06-26 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition containing quinolones and method of use |
| ES2671342T3 (es) * | 2006-02-10 | 2018-06-06 | Pari Pharma Gmbh | Antibióticos nebulizados para terapia de inhalación |
| WO2008005276A2 (en) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| PH12016501747B1 (en) * | 2010-02-25 | 2022-06-22 | Daiichi Sankyo Co Ltd | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
-
2010
- 2010-12-16 PH PH1/2016/501747A patent/PH12016501747B1/en unknown
- 2010-12-16 SG SG2012061842A patent/SG183427A1/en unknown
- 2010-12-16 MX MX2012009844A patent/MX349603B/es active IP Right Grant
- 2010-12-16 KR KR1020127024069A patent/KR20130043611A/ko not_active Ceased
- 2010-12-16 US US13/580,931 patent/US20120316158A1/en not_active Abandoned
- 2010-12-16 WO PCT/JP2010/072685 patent/WO2011104981A1/ja not_active Ceased
- 2010-12-16 NZ NZ602126A patent/NZ602126A/xx not_active IP Right Cessation
- 2010-12-16 BR BR112012021247-8A patent/BR112012021247A2/pt not_active Application Discontinuation
- 2010-12-16 PH PH1/2012/501674A patent/PH12012501674A1/en unknown
- 2010-12-16 MY MYPI2012003769A patent/MY183483A/en unknown
- 2010-12-16 EA EA201290827A patent/EA201290827A1/ru unknown
- 2010-12-16 ES ES10846644.2T patent/ES2568647T3/es active Active
- 2010-12-16 EP EP10846644.2A patent/EP2540299B1/en not_active Not-in-force
- 2010-12-16 CN CN2010800646540A patent/CN102770141A/zh active Pending
- 2010-12-16 JP JP2010280325A patent/JP5600056B2/ja active Active
- 2010-12-16 KR KR1020177015979A patent/KR20170070265A/ko not_active Ceased
- 2010-12-16 CA CA2791190A patent/CA2791190C/en not_active Expired - Fee Related
- 2010-12-28 TW TW099146206A patent/TWI488627B/zh not_active IP Right Cessation
-
2012
- 2012-03-12 JP JP2012054761A patent/JP2012162532A/ja active Pending
-
2013
- 2013-08-16 JP JP2013169146A patent/JP5674882B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG183427A1 (en) | 2012-09-27 |
| NZ602126A (en) | 2013-10-25 |
| WO2011104981A1 (ja) | 2011-09-01 |
| JP5600056B2 (ja) | 2014-10-01 |
| MX2012009844A (es) | 2012-09-21 |
| PH12016501747A1 (en) | 2019-02-11 |
| JP2013241464A (ja) | 2013-12-05 |
| KR20130043611A (ko) | 2013-04-30 |
| JP5674882B2 (ja) | 2015-02-25 |
| EA201290827A1 (ru) | 2013-03-29 |
| EP2540299A4 (en) | 2013-07-24 |
| CN102770141A (zh) | 2012-11-07 |
| BR112012021247A2 (pt) | 2018-04-03 |
| AU2010346703A1 (en) | 2012-09-20 |
| ES2568647T3 (es) | 2016-05-03 |
| TWI488627B (zh) | 2015-06-21 |
| CA2791190C (en) | 2017-12-12 |
| KR20170070265A (ko) | 2017-06-21 |
| JP2011195564A (ja) | 2011-10-06 |
| PH12012501674A1 (en) | 2012-11-05 |
| US20120316158A1 (en) | 2012-12-13 |
| EP2540299A1 (en) | 2013-01-02 |
| EP2540299B1 (en) | 2016-04-13 |
| CA2791190A1 (en) | 2011-09-01 |
| MX349603B (es) | 2017-08-03 |
| MY183483A (en) | 2021-02-20 |
| TW201129364A (en) | 2011-09-01 |
| JP2012162532A (ja) | 2012-08-30 |
| HK1177887A1 (en) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001978A (es) | Compuestos antibioticos. | |
| WO2012003474A3 (en) | Compositions and methods related to protein a (spa) variants | |
| NZ593111A (en) | Antibacterial compounds | |
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| MX348974B (es) | Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. | |
| MX2019012877A (es) | Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago. | |
| NZ713621A (en) | Compounds and methods of treating infections | |
| WO2015002932A8 (en) | Antimicrobial compositions comprising hypochlorous acid and silver | |
| WO2012034077A3 (en) | Compositions and methods related to attenuated staphylococcal strains | |
| ZA202002093B (en) | Antibacterial compounds | |
| Dantam et al. | Biocidal efficacy of silver-impregnated contact lens storage cases in vitro | |
| PH12012501674A1 (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof | |
| MY209256A (en) | Compounds affecting pigment production and use thereof for treatment of bacterial diseases | |
| EP2046287A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING INFECTIONS | |
| WO2015112980A3 (en) | Dermaseptin-type and piscidin-type antimicrobial peptides | |
| MX2016009251A (es) | Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos. | |
| MX2016003046A (es) | Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos. | |
| BR112014026861A2 (pt) | antígenos de estafilococos coagulase e métodos de seu uso | |
| NZ628927A (en) | Compounds and methods for treating candidiasis and aspergillus infections | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| GB2541840A (en) | Ophthalmic composition for the treatment of ocular infection | |
| HK1243951A1 (zh) | 抗微生物组合和其在治疗微生物感染中的用途 | |
| WO2016108930A3 (en) | Antisense antibacterial compounds and methods | |
| MX2009006325A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| MY182591A (en) | Compositions for use in treating eye disorders using dipyridamole |